2-chloro-3,4-dihydro-2-(2-hydroxy-5-methoxyphenyl)-4-methyl-3-oxo-2H-1,4-benzothiazine | 105796-59-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并噻嗪类
• 英文名称: 2-chloro-3,4-dihydro-2-(2-hydroxy-5-methoxyphenyl)-4-methyl-3-oxo-2H-1,4-benzothiazine
• 英文别名: 2-chloro-2-(2-hydroxy-5-methoxyphenyl)-4-methyl-1,4-benzothiazin-3-one
• CAS: 105796-59-6
• 化学式: C₁₆H₁₄ClNO₃S
• 分子量: 335.811
• InChiKey: COLHRQKNJOIQBV-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.4
• 重原子数：
  22
• 可旋转键数：
  2
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.19
• 拓扑面积：
  75.1
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  2-chloro-3,4-dihydro-2-(2-hydroxy-5-methoxyphenyl)-4-methyl-3-oxo-2H-1,4-benzothiazine 以 甲醇 为溶剂， 以11.8 g (85.3%)的产率得到3,4-二氢-2-(2-羟基-5-甲氧基苯基)-2-甲氧基-4-甲基-3-氧代-2H-1,4-苯并噻嗪
  参考文献：
  名称：

  2-phenyl-1,4-benzothiazin-3-one derivatives

  摘要：

  该发明涉及公式[I]及其盐的2-芳基苯并噻吩衍生物，制备过程和用于循环系统疾病的治疗药物，其中R1和R2相同或不同，可以是氢，低碳基，羟基，低烷氧基，酰氧基，四氢吡喃氧基，卤素，硝基，氨基，低烷基氨基或[式II]，低烷氧基基团可以被卤素，甲酰基，低烷氧基或环氧基取代；R3是氢或低烷基；R4是氢，低烷基，环烷基，羟基，低烷氧基，巯基，低烷硫基，芳基硫基，卤素，氰基，甲酰基-低烷基，低烷氧基-低烷基或[式III]，R5，R6，R7和R8相同或不同，可以是氢，低烷基，环烷基，酰基，苯基，吡啶基或取代的低烷基，苯基或吡啶基可以被低烷基，羟基，低烷氧基，低烷基二氧基，卤素，硝基，氰基，低烷酰氧基或卤代低烷基取代，取代的低烷基的取代基是羟基，苯基，苯氧基，苯基羰基或吡啶基，并且苯环，苯氧基或苯基羰基基团和吡啶基还可以进一步被低烷基，羟基，低烷氧基，低烷基二氧基，卤素，硝基，氰基，低烷酰氧基或卤代低烷基重新取代；R5和R6以及R7和R8可以连接成哌啶，哌嗪或吗啉环，哌啶或哌嗪环可以被低烷基，苯基，羟基-低烷基，苯基-低烷基，苯基羰基，苯基羰基-低烷基，苯基-(羟基)低烷基，苯基-低烯基羰基或萘氧-(羟基)低烷基取代，苯环，苯基-低烷基，苯基羰基，苯基羰基-低烷基，苯基-(羟基)低烷基或苯基-低烯基羰基基团还可以进一步被低烷基，低烷氧基，烷二氧基或卤素重新取代；Z是氢，低烷基，低烷氧基，羟基，卤素，氰基，硝基，卤代低烷基或低烷基酰氧基；A是直链或支链低碳烷基；B是直链或支链低碳烷基，可以被羟基取代；n为0或1，当n为0时，R4和Z不能同时表示氢原子。

  公开号：

  US04739050A1
• 作为产物：
  描述：

  3,4-Dihydro-2-(2-hydroxy-5-methoxyphenyl)-4-methyl-3-oxo-2H-1,4-benzothiazine 在 磺酰氯 作用下， 以 二氯甲烷 为溶剂， 反应 1.0h， 以79%的产率得到2-chloro-3,4-dihydro-2-(2-hydroxy-5-methoxyphenyl)-4-methyl-3-oxo-2H-1,4-benzothiazine
  参考文献：
  名称：

  Synthesis and calcium ion antagonistic activity of 2-[2-[(aminoalkyl)oxy]-5-methoxyphenyl]-3,4-dihydro-4-methyl-3-oxo-2H-1,4-benzothiazines

  摘要：

  As an extension of the previous investigation (J. Med. Chem. 1988, 31, 919), we synthesized a series of 2-[2-[(aminoalkyl)oxy]-5-methoxyphenyl]-3,4-dihydro-4-methyl-3-oxo-2H- 1,4-benzothiazines (3) and evaluated their Ca2+ antagonistic activities. Ca2+ antagonistic activity was measured with isolated depolarized guinea pig taenia cecum. On the basis of their potent Ca2+ antagonistic activity, six benzothiazines were selected and further evaluated for their vasocardioselectivity. Among these six compounds, the key compound 15 [3,4-dihydro-2-[5-methoxy-2-[3-[N-methyl-N-[2-[3,4- (methylenedioxy)phenoxy]ethyl]amino]propoxy]phenyl]-4-methyl-3-oxo- 2H-1,4-benzothiazine hydrogen fumarate] was recognized as having the lowest cardioselectivity. Following optical resolution, the absolute configuration of the compound's optically active enantiomer was determined by means of X-ray crystallography of a synthetic precursor (+)-4a. The Ca2+ antagonistic activity of 15 was found to reside primarily in (+)-15 (which was about 7 times more potent than (-)-15). The in vitro study showed that (+)-15 had a low cardioselectivity compared to verapamil and diltiazem. This result suggests that (+)-15 would exhibit less adverse effects due to cardiac inhibition than diltiazem and verapamil in therapeutic use.

  DOI：

  10.1021/jm00169a011

文献信息

• 2-phenyl-1,4-benzothiazin-3-one derivatives
  申请人：Santen Pharmaceutical Co., Ltd.

  公开号：US04739050A1

  公开（公告）日：1988-04-19

  This invention relates to 2-arylbenzothiazine derivatives of the formula[I] and salts thereof, process of preparation and therapeutic drug comprising them for circulatory diseases, ##STR1## wherein R.sup.1 and R.sup.2 are the same or different and are hydrogen, lower alkyl, hydroxy, lower alkoxy, acyloxy, tetrahydropyranyloxy, halogen, nitro, amino, lower alkylamino or ##STR2## and the lower alkoxy group may be substituted by halogen, formyl, lower alkoxy or epoxy; R.sup.3 is hydrogen or lower alkyl; R.sup.4 is hydrogen, lower alkyl, cycloalkyl, hydroxy, lower alkoxy, mercapto, lower alkylthio, arylthio, halogen, cyano, formyl-lower alkyl, lower alkoxy-lower alkyl or ##STR3## R.sup.5,R.sup.6,R.sup.7 and R.sup.8 are the same or different and are hydrogen, lower alkyl, cycloalkyl, acyl, phenyl, pyridyl or substituted lower alkyl, and the phenyl or pyridyl group may be substituted by lower alkyl, hydroxy, lower alkoxy, lower alkylenedioxy, halogen, nitro, cyano, lower alkanoyloxy or halogeno-lower alkyl, and the substituent(s) of the substituted lower alkyl is(are) hydroxy, phenyl, phenyloxy, phenylcarbonyl or pyridyl, and such phenyl ring of the phenyl, phenyloxy or phenylcarbonyl group and the pyridyl group may further be resubstituted by lower alkyl, hydroxy, lower alkoxy, lower alkylenedioxy, halogen, nitro, cyano, lower alkanoyloxy or halogeno lower alkyl; R.sup.5 and R.sup.6, and R.sup.7 and R.sup.8 may join to form piperidine, piperazine or morpholine ring, and the piperidine or piperazine ring may be substituted by lower alkyl, phenyl, hydroxy-lower alkyl, phenyl-lower alkyl, phenylcarbonyl, phenylcarbonyl-lower alkyl, spheny-(hydroxy) lower alkyl, phenyl-lower alkenylcarbonyl or naphthoxy-(hydroxy)lower alkyl, and such phenyl ring of the phenyl, phenyl-lower alkyl, phenylcarbonyl, phenylcarbonyl-lower alkyl, phenyl-(hydroxy)lower alkyl or phenyl-lower alkenylcarbonyl group may further be resubstituted by lower alkyl, lower alkoxy, alkylenedioxy or halogen; Z is hydrogen, lower alkyl, lower alkoxy, hydroxy, halogen, cyano, nitro, halogeno-lower alkyl or lower alkanoyloxy; A is straight or branched lower alkylene; B is straight or branched lower alkylene which may be substituted by hydroxy; and n is 0 or 1, and when n is 0, both R.sup.4 and Z are not represent hydrogen atom at the same time.

  该发明涉及公式[I]及其盐的2-芳基苯并噻吩衍生物，制备过程和用于循环系统疾病的治疗药物，其中R1和R2相同或不同，可以是氢，低碳基，羟基，低烷氧基，酰氧基，四氢吡喃氧基，卤素，硝基，氨基，低烷基氨基或[式II]，低烷氧基基团可以被卤素，甲酰基，低烷氧基或环氧基取代；R3是氢或低烷基；R4是氢，低烷基，环烷基，羟基，低烷氧基，巯基，低烷硫基，芳基硫基，卤素，氰基，甲酰基-低烷基，低烷氧基-低烷基或[式III]，R5，R6，R7和R8相同或不同，可以是氢，低烷基，环烷基，酰基，苯基，吡啶基或取代的低烷基，苯基或吡啶基可以被低烷基，羟基，低烷氧基，低烷基二氧基，卤素，硝基，氰基，低烷酰氧基或卤代低烷基取代，取代的低烷基的取代基是羟基，苯基，苯氧基，苯基羰基或吡啶基，并且苯环，苯氧基或苯基羰基基团和吡啶基还可以进一步被低烷基，羟基，低烷氧基，低烷基二氧基，卤素，硝基，氰基，低烷酰氧基或卤代低烷基重新取代；R5和R6以及R7和R8可以连接成哌啶，哌嗪或吗啉环，哌啶或哌嗪环可以被低烷基，苯基，羟基-低烷基，苯基-低烷基，苯基羰基，苯基羰基-低烷基，苯基-(羟基)低烷基，苯基-低烯基羰基或萘氧-(羟基)低烷基取代，苯环，苯基-低烷基，苯基羰基，苯基羰基-低烷基，苯基-(羟基)低烷基或苯基-低烯基羰基基团还可以进一步被低烷基，低烷氧基，烷二氧基或卤素重新取代；Z是氢，低烷基，低烷氧基，羟基，卤素，氰基，硝基，卤代低烷基或低烷基酰氧基；A是直链或支链低碳烷基；B是直链或支链低碳烷基，可以被羟基取代；n为0或1，当n为0时，R4和Z不能同时表示氢原子。
• FUJITA, MASANOBU;ITO, SUSUMU;OTA, ATSUTOSHI;KATO, NOBUHARU;YAMAMOTO, KOJI+, J. MED. CHEM., 33,(1990) N, C. 1898-1905
  作者：FUJITA, MASANOBU、ITO, SUSUMU、OTA, ATSUTOSHI、KATO, NOBUHARU、YAMAMOTO, KOJI+

  DOI：——

  日期：——
• US4739050A
  申请人：——

  公开号：US4739050A

  公开（公告）日：1988-04-19
• Synthesis and calcium ion antagonistic activity of 2-[2-[(aminoalkyl)oxy]-5-methoxyphenyl]-3,4-dihydro-4-methyl-3-oxo-2H-1,4-benzothiazines
  作者：Masanobu Fujita、Susumu Ito、Atsutoshi Ota、Nobuharu Kato、Koji Yamamoto、Yoichi Kawashima、Hideyasu Yamauchi、Junichi Iwao

  DOI：10.1021/jm00169a011

  日期：1990.7

  As an extension of the previous investigation (J. Med. Chem. 1988, 31, 919), we synthesized a series of 2-[2-[(aminoalkyl)oxy]-5-methoxyphenyl]-3,4-dihydro-4-methyl-3-oxo-2H- 1,4-benzothiazines (3) and evaluated their Ca2+ antagonistic activities. Ca2+ antagonistic activity was measured with isolated depolarized guinea pig taenia cecum. On the basis of their potent Ca2+ antagonistic activity, six benzothiazines were selected and further evaluated for their vasocardioselectivity. Among these six compounds, the key compound 15 [3,4-dihydro-2-[5-methoxy-2-[3-[N-methyl-N-[2-[3,4- (methylenedioxy)phenoxy]ethyl]amino]propoxy]phenyl]-4-methyl-3-oxo- 2H-1,4-benzothiazine hydrogen fumarate] was recognized as having the lowest cardioselectivity. Following optical resolution, the absolute configuration of the compound's optically active enantiomer was determined by means of X-ray crystallography of a synthetic precursor (+)-4a. The Ca2+ antagonistic activity of 15 was found to reside primarily in (+)-15 (which was about 7 times more potent than (-)-15). The in vitro study showed that (+)-15 had a low cardioselectivity compared to verapamil and diltiazem. This result suggests that (+)-15 would exhibit less adverse effects due to cardiac inhibition than diltiazem and verapamil in therapeutic use.
• 2-ARYLBENZOTHIAZINE DERIVATIVES
  申请人：SANTEN PHARMACEUTICAL CO., LTD.

  公开号：EP0233291B1

  公开（公告）日：1991-03-13